3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumor, Pleural
1
Seminoma
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Osteolysis
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Hypercalcemia
1
Hematologic Neoplasms
1
Fractures, Spontaneous
1
Colorectal Cancer Metastatic
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms
1
Bone Diseases, Metabolic
1
Anemia
1
Amyloidosis
1
Interventions
Pemetrexed
3
Gemcitabine
3
Topotecan
2
Carboplatin
2
vosaroxin
1
vinflunine
1
taxane
1
pembrolizumab
1
lurtotecan
1
liposomal doxorubicin
1
enzalutamide
1
bemiparin
1
apalutamide
1
abiraterone
1
Vinorelbine
1
Temozolomide
1
RRx-001
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Ipilimumab
1
Etoposide
1
Docetaxel
1
Cisplatin
1
BI 2536
1
Arsenic Trioxide
1
ARQ 197
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Small Cell
×
ARQ 197
×
Clear all
NCT02608411
2023-10-13
TIMES
Istituto Oncologico Veneto IRCCS
Phase 2
Terminated
5 enrolled